Physician profile
Eric J Bergson
NPI 1831160688
$2,447.13
in general payments reported to CMS, 2019-2025
27 companies · $456 in 2025
The $456 reported for 2025 was more than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $498 · 2020: $46.12 · 2021: $118 · 2022: $390 · 2023: $446 · 2024: $494 · 2025: $456.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,395.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,395.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $682.97 | 2022-2025 | Inspire |
| Glaxosmithkline, LLC. | $259.74 | 2021-2025 | Nucala |
| Regeneron Healthcare Solutions, INC. | $187.22 | 2019-2025 | Dupixent |
| Genzyme Corporation | $169.42 | 2019-2024 | |
| Optinose US, INC. | $123.98 | 2019-2025 | |
| Stryker Corporation | $122.24 | 2019 | |
| Kaleo, INC. | $115.19 | 2021-2024 | Auvi-Q |
| Arrinex, INC. | $97.99 | 2019 | |
| Medtronic USA, INC. | $90.90 | 2019-2020 | |
| Hikma Pharmaceuticals USA | $62.73 | 2023-2025 | Ryaltris |
| Neurent Medical Limited | $56.18 | 2024 | Neuromark Radiofrequency Console, Neuromark Device |
| Medtronic, INC. | $55.93 | 2024 | Propel |
| Novartis Pharmaceuticals Corporation | $50.07 | 2019 | |
| Genentech USA, INC. | $42.44 | 2024-2025 | Xolair |
| Intersect Ent, INC. | $42.24 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $36.07 | 2024 | Bridion |
| Checkpoint Surgical, INC | $33.56 | 2025 | Checkpoint Stimulators |
| Integra Lifesciences Corporation | $33.00 | 2024 | Inspira Air, Acclarent Aera, Relieva Spinplus Nav |
| Phadia US INC. | $31.56 | 2021-2024 | Immunocap |
| Smith+Nephew, INC. | $24.89 | 2019 | |
| Ars Pharmaceuticals Operations, INC. | $24.01 | 2025 | Neffy |
| Amgen INC. | $21.04 | 2021 | |
| Paratek Pharmaceuticals, INC. | $19.37 | 2025 | Xhance |
| Takeda Pharmaceuticals U.S.A., INC. | $18.88 | 2024 | Eohilia |
| Alk-Abello, INC | $16.89 | 2024 | Grastek, Ragwitek, Odactra |
| Kowa Pharmaceuticals America, INC. | $14.44 | 2022 | |
| Sanofi-Aventis U.S. LLC | $14.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Bergson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.